TEL: 044-952-0102


Global Cardiac Biomarkers Market - Segmented by Type Of Marker, Application, Location Of Testing and Geography - Growth, Trends, and Forecast (2018 - 2023)

発行 Mordor Intelligence LLP 商品コード 567965
出版日 ページ情報 英文 112 Pages
納期: 2-3営業日
本日の銀行送金レート: 1USD=109.25円で換算しております。
Back to Top
心臓バイオマーカーの世界市場:成長率・傾向・予測 Global Cardiac Biomarkers Market - Segmented by Type Of Marker, Application, Location Of Testing and Geography - Growth, Trends, and Forecast (2018 - 2023)
出版日: 2018年05月01日 ページ情報: 英文 112 Pages

当レポートでは、世界の心臓バイオマーカーの市場について分析し、技術の概要や市場の基本構造、主な市場促進・抑制要因、市場規模の動向見通し (今後6年間分)、マーカー別・用途別・実施地点別・地域別の詳細動向、市場競争の動き、主要企業のプロファイル、今後の市場の方向性などを調査しております。

第1章 イントロダクション

第2章 エグゼクティブ・サマリー

第3章 主な影響要因

第4章 市場概要

  • 現在の市場シナリオ
  • ポーターのファイブフォース分析

第5章 市場の促進要因・抑制要因・機会・課題の分析 (DROC分析)

  • 市場促進要因
  • 市場抑制要因
  • 現在の市場機会
  • 主な課題

第6章 市場区分

  • マーカーの種類別
    • クレアチンキナーゼ
    • トロポニン (T,I)
    • ミオグロビン
    • ナトリウム利尿ペプチド (BNP、NT-proBNP)
    • 虚血修飾アルブミン
    • その他
  • 用途別
    • 心筋梗塞
    • 鬱血性心不全
    • 急性冠症候群
    • アテローム性動脈硬化
    • その他
  • 試験の実施地点別
    • POC (Point of Care:臨床現場) 検査
    • 試験室検査
  • 地域別
    • 北米 (米国、カナダ、メキシコ)
    • 欧州 (英国、スペイン、イタリア、フランス、ドイツなど)
    • アジア太平洋地域 (日本、中国、インド、韓国、オーストラリア・ニュージーランドなど)
    • 中東・アフリカ (湾岸協力会議 (GCC) 諸国、南アフリカなど)
    • 南米 (ブラジル、アルゼンチンなど)

第7章 競争環境

  • 企業合併・買収 (M&A)
  • 協定、事業協力・提携
  • 新製品の発売

第8章 企業プロファイル

  • Abbott laboratories
  • Alere Inc.
  • Siemens Healthcare
  • Roche Diagnostics Corporation
  • Beckman Coulter
  • Becton, Dickinson And Co.
  • Thermo Fisher Scientific
  • BioMerieux
  • Bio-Rad Laboratories
  • Randox laboratories

第9章 今後の市場シナリオ

Product Code: 54449

The cardiac biomarkers market is expected to register a CAGR of about 18.5%, during the forecast period. Biomarkers have an essential role in the diagnosis, management, risk stratification, and clinical decision-making in the patients suffering from disease. Cardiac biomarkers are measurable and quantifiable biological parameters, which are detected in the blood and serve as indices for physiological and pathological assessment by a specialized immunoassay.

Increasing Prevalence of Cardiovascular Diseases

Myocardial infarction is caused is one of the conditions that occur due to cardiovascular diseases. It causes significant mortality and morbidity. Timely diagnosis of heart conditions allow clinicians to analyze the risk of their patients and prescribe relevant treatment. Biomarkers enable us for timely identification of cardiovascular conditions and help patients prevent conditions, like myocardial infarction and acute coronary syndrome. Increasing awareness about early diagnosis using cardiovascular biomarkers among patients and healthcare providers, along with factors, like growing funding from public and private organizations for R&D and technological advancements using cardiac will drive the market in the forecasted period.

Stringent Regulation

After the identification of a biomarker data from the discovery tools indicate that it may answer the clinical question posed, its successful translation will require an assay that must meet stringent requirements. This step represents a critical cause of failure for biomarkers, as the development of a robust and reproducible assay, with appropriate sensitivity, specificity, and precision, depends on a standards-based discovery process. For assays to be submitted for FDA qualification or clinical validation the test must be analytically validated and, depending on the targeted clinical application, evaluated in one or more clinical trials. Finally, as the assay moves to later discovery, it is important to define how clinical decision making will be impacted by the assay, and increasingly careful considerations to the economics of manufacturing, competing technologies, and scale must also be considered. All these steps require a lot of time and slow down the overall development process. Other factors, such as poor reimbursement policies will restrain the market growth.

Geographical or Segment Scenario

North America is projected to lead the global market, as there is a high demand for testing due to high rate of CVD prevalence and growing awareness towards application cardiac biomarkers in cardiac diagnostics. Asia-Pacific is estimated to register the fastest CAGR owing to the increasing disposable incomes, affordable solutions, and increased funding in R&D in the field advanced cardiac treatments.

Key Developments in the Market

January 2017 - Roche announced that it has received the 510(k) clearance for its Elecsys Troponin T Gen 5 STAT (TnT Gen 5 STAT) blood test for patients with a suspected heart attack


Reasons to Purchase this Report

Current and future cardiac biomarkers market outlook in the developed and emerging markets

Analysis of various perspectives of the market with the help of Porter's five forces analysis

The segment that is expected to dominate the market

Regions that are expected to witness fastest growth during the forecast period

Identify the latest developments, market shares, and strategies employed by the major market players

3 months analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Product and Services
    • 5.2.5 Competitive Rivalry Within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Increasing Prevalence Of Cardiovascular Diseases
    • 6.1.2 Technological Advancements Using Cardiac Biomarkers
    • 6.1.3 Growing Funding From Public and Private Organizations for R&D
  • 6.2 Market Restraints
    • 6.2.1 Stringent Regulation
    • 6.2.2 Poor Reimbursement Policies
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Type Of Marker
    • 7.1.1 Creatine Kinase
    • 7.1.2 Troponins (T,I)
    • 7.1.3 Myoglobin
    • 7.1.4 Natriuretic Peptides (BNP And NT-ProBNP)
    • 7.1.5 Ischemia Modified Albumin
    • 7.1.6 Others
  • 7.2 By Application
    • 7.2.1 Myocardial Infarction
    • 7.2.2 Congestive Heart Failure
    • 7.2.3 Acute Coronary Syndrome
    • 7.2.4 Atherosclerosis
    • 7.2.5 Others
  • 7.3 By Location Of Testing
    • 7.3.1 Point of Care Testing
    • 7.3.2 Laboratory Testing
  • 7.4 By Geography
    • 7.4.1 North America
      • United States
      • Canada
      • Mexico
    • 7.4.2 Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
      • Rest of Europe
    • 7.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia & New Zealand
      • South Korea
      • Rest of Asia-Pacific
    • 7.4.4 Middle East & Africa
      • GCC
      • South Africa
      • Rest of the Middle East & Africa
    • 7.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.2 Alere Inc.
  • 9.3 Beckman Coulter
  • 9.4 Becton, Dickinson And Co.
  • 9.5 Biomerieux
  • 9.6 Bio-Rad Laboratories
  • 9.7 Randox Laboratories
  • 9.8 Roche Diagnostics Corporation
  • 9.9 Siemens Healthcare
  • 9.10 Thermo Fisher Scientific
  • 9.11 List Not Exhaustive

10. Future of the Market

Back to Top